Zirconium silicate (ZS)
Phase 3Small molecule
Zirconium silicate (ZS) is one of 39 small molecule programs targeting Hyperkalemia. It is currently in Phase 3.
2
Indications
2
Total Trials
0
Active Trials
38
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
540 competitors in Chronic Kidney Disease
#DrugCompanyPhaseTrials
1Epogen
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.Preclinical
Zirconium silicate (ZS)
ZZS Pharma, Inc.
Phase 3
Uloric
TakedaPreclinical
Glucotrol
PfizerPreclinical
Sovaldi
GileadPreclinical
Lorelco
SanofiPreclinical
Flomax
SanofiPreclinical
Miochol
BBausch Health Americas, Inc.
Preclinical
Epoetin Beta
RochePreclinical
Baraclude
KKaruna Therapeutics, Inc., a Bristol Myers Squibb company
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Zirconium silicate (ZS). EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- ZZS Pharma, Inc.